There is a lack of studies reporting on the outcome of treatment control of central neurocytomas. The management of neurocytomas has been guided by retrospective case reports, institutional case series, and meta-analysis of institutional experiences [6, 14, 25]. Surgery is the primary modality of initial intervention, with watchful waiting (surveillance) not documented as a common primary option [1, 19]. Despite the indolent nature of these tumors, most patients are symptomatic at presentation, with increased intracranial pressure due to mass effect or hydrocephalus, and thus they require intervention rather than surveillance. Clinically, the tumor causes signs of increased intracranial pressure, visual and mental disturbances, and occasionally, pyramidal or endocrine signs and symptoms. Rarely, neurocytomas may be discovered incidentally with no clinical symptoms.

In our study, the tumor was located predominantly in the left ventricle, in 41.6 % of cases, while it was biventricular in 33.3 % of cases. All the tumors were in the body of the ventricles attached to the septum, while Shin et al. [22] reported that 50 % of central neurocytomas had a typical location in the lateral ventricle around the foramen of Monro and 15 % had biventricular location.

The majority of neurocytomas are benign. In our study 30 % of cases showed an MIB LI of >2 % and were considered to be of an aggressive nature.

Brat et al. [2] and Soylemezoglu et al. [23] found that approximately 25 % of these rare CNS tumors were more aggressive, with an MIB-1 LI of >2 % or atypical histological features.